Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative drugs work by mimicking the natural actions of GLP-1, a hormone released by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these substances boost insulin release and suppress glucagon output,

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing contrasts in their